ESP Diagnostics

Executive Summary

ESP Diagnostics is a UK-based biotechnology company dedicated to advancing early diagnosis of neurodegenerative diseases, a critical unmet need in global healthcare. Founded in 2010 and headquartered in London, the company develops and manufactures diagnostic tests and reagents for clinical laboratories. While the company has not disclosed funding or product pipeline details, its focus on neurodegenerative diagnostics—particularly for conditions like Alzheimer's and Parkinson's—positions it in a high-growth market with significant demand. The company's private status and lack of disclosed stage suggest it may be in early development, but its long operating history indicates persistence in a challenging field. ESP Diagnostics aims to enable earlier intervention and better patient outcomes through innovative diagnostic solutions, potentially reducing healthcare burden and improving quality of life for millions worldwide.

Upcoming Catalysts (preview)

• Q4 2026Launch of a novel blood-based diagnostic test for Alzheimer's disease35% success
• Q2 2027CE marking or FDA clearance for a flagship diagnostic product40% success
• TBDStrategic partnership with a major pharmaceutical or hospital network45% success